TransCode Therapeutics (RNAZ) started dosing the first patient in the fourth cohort of its phase 1 cancer treatment trial.
Two more patients in the cohort are set to receive the TTX-MC138 "to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer," the company said Thursday in a statement.
"No significant safety or dose limiting toxicities have been reported," and additional patients are being evaluated for expanded enrollment, the company said.
Shares of the company rose 28% in after-hours trading.
Price: 0.6650, Change: +0.15, Percent Change: +27.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。